Re: Farmas USA
Announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of its proprietary fully-human anti-PD-L1 monoclonal antibody.
Ains que brinco me he perdido cagon'sos
TGTX
Keryx price target raised to $34 from $25 at Mizuho
Mizuho believes investors are under appreciating the potential of this week's Doc Fix bill that delays oral bundling to 2024 from 2016. The firm significantly raised Keryx's Zerenex revenue forecast and now sees peak sales closer to $2B from $1B. The firm rates shares a Buy with a $34 price target, up from $25
KERX